Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome
1Department of Pediatrics, University of Chicago, IL 60637.
Abstract:
Cyclic AMP production was studied in platelets from 31 patients with fragile X syndrome, 16 patients with mental retardation, 4 patients with autistic disorder, and 57 control individuals. 1-isobutyl-3-methylxanthine (IBMX) was used to inhibit phosphodiesterase; prostaglandin E1 (PGE1), to stimulate cAMP production via a receptor-dependent mechanism, and forskolin (FSK), to directly activate the catalytic subunit. Cyclic AMP production in IBMX, PGE1 + IBMX, and FSK + IBMX was 50% (P < 0.05), 65% (P = 0.001), and 53% (P = 0.001), respectively, in fragile X platelets relative to controls. Cyclic AMP production was not statistically different from controls in patients with mental retardation or autistic disorder. There was no effect of age or sex on cAMP production. Dose response curves suggested that abnormal cAMP production was due to diminished maximal response rather than altered potency of stimulating agents. The data presented here demonstrate that diminished cAMP production exists in platelets from patients with fragile X syndrome. Thus, defective functioning of cAMP-mediated regulatory signalling pathways in fragile X brain may contribute to the mental deficiency in these patients.
Insights
Platelets from fragile X syndrome patients show significantly reduced cyclic AMP (cAMP) production. This suggests impaired cAMP signaling pathways may contribute to the cognitive deficits observed in fragile X syndrome.
Area of Science:
- Biochemistry
- Neuroscience
- Genetics
Background:
- Fragile X syndrome is a genetic disorder causing intellectual disability.
- Cyclic AMP (cAMP) is a crucial second messenger involved in various cellular processes, including neuronal function.
- Dysregulation of cAMP signaling pathways has been implicated in neurodevelopmental disorders.
Purpose of the Study:
- To investigate cyclic AMP (cAMP) production in platelets of individuals with fragile X syndrome.
- To compare cAMP levels in fragile X syndrome patients with those having mental retardation, autistic disorder, and healthy controls.
- To explore the potential role of cAMP signaling defects in the pathophysiology of fragile X syndrome.
Main Methods:
- Platelet samples were collected from 31 fragile X syndrome patients, 16 with mental retardation, 4 with autistic disorder, and 57 controls.
- Cyclic AMP (cAMP) production was measured using phosphodiesterase inhibition (IBMX), receptor-dependent stimulation (prostaglandin E1 + IBMX), and direct catalytic activation (forskolin + IBMX).
- Dose-response curves were analyzed to determine the nature of the cAMP production defect.
Main Results:
- Platelets from fragile X syndrome patients exhibited significantly reduced cAMP production across all tested conditions (IBMX, PGE1 + IBMX, FSK + IBMX) compared to controls (50-65% reduction, P < 0.05).
- No significant differences in cAMP production were observed between patients with mental retardation or autistic disorder and controls.
- The diminished cAMP response in fragile X syndrome was attributed to a reduced maximal response, not altered potency of stimulating agents.
Conclusions:
- This study demonstrates diminished cAMP production in platelets from individuals with fragile X syndrome.
- These findings suggest a potential defect in cAMP-mediated regulatory signaling pathways in the fragile X brain.
- Impaired cAMP signaling may contribute to the mental deficiency associated with fragile X syndrome.
More Related Videos
11:10Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024